Compounds > imatinib mesylate
Page last updated: 2024-09-03

imatinib mesylate and Thrombotic Microangiopathies

imatinib mesylate has been researched along with Thrombotic Microangiopathies in 6 studies

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's5 (83.33)24.3611
2020's1 (16.67)2.80

Authors

AuthorsStudies
Fujioka, M; Hara, T; Hirata, KI; Suzuki, M; Taniguchi, Y; Yoshikawa, S1
Imai, Y; Kario, K; Kubota, K; Shinozaki, T1
Matsubara, H; Matsubara, O; Ogawa, A; Yamadori, I1
Abe, H; Araki, K; Fujino, T; Fukada, I; Hatano, M; Ito, Y; Iwase, T; Minatsuki, S; Numakura, S; Ushiku, T1
Aujoulat, O; Chantrel, F; Debliquis, A; Eisenmann, JC; Guillon, M; Hinschberger, O; Kenizou, D; Merieau, S; Ojeda-Uribe, M; Veyradier, A1
Abe, H; Fukayama, M; Hatano, M; Imamura, T; Inaba, T; Kinugawa, K; Komuro, I; Maki, H; Minatsuki, S; Miura, I; Muraoka, H; Nagai, R; Tanaka, M; Yao, A; Yao, T1

Other Studies

6 other study(ies) available for imatinib mesylate and Thrombotic Microangiopathies

ArticleYear
Imatinib Dramatically Improved Pulmonary Hypertension Caused by Pulmonary Tumor Thrombotic Microangiopathy (PTTM) Associated with Metastatic Breast Cancer.
    International heart journal, 2020, May-30, Volume: 61, Issue:3

    Topics: Adult; Antineoplastic Agents; Breast Neoplasms; Female; Humans; Hypertension, Pulmonary; Imatinib Mesylate; Thrombotic Microangiopathies

2020
Imatinib dramatically alleviates pulmonary tumour thrombotic microangiopathy induced by gastric cancer.
    BMJ case reports, 2017, Sep-07, Volume: 2017

    Topics: Carcinoma, Signet Ring Cell; Fatal Outcome; Female; Humans; Hypertension, Pulmonary; Imatinib Mesylate; Lung Neoplasms; Middle Aged; Protein Kinase Inhibitors; Rare Diseases; Receptors, Platelet-Derived Growth Factor; Stomach Neoplasms; Thrombotic Microangiopathies; Tomography, X-Ray Computed

2017
Pulmonary tumor thrombotic microangiopathy with circulatory failure treated with imatinib.
    Internal medicine (Tokyo, Japan), 2013, Volume: 52, Issue:17

    Topics: Antineoplastic Agents; Benzamides; Female; Humans; Imatinib Mesylate; Middle Aged; Neoplastic Cells, Circulating; Piperazines; Pyrimidines; Thrombotic Microangiopathies

2013
Imatinib alleviated pulmonary hypertension caused by pulmonary tumor thrombotic microangiopathy in a patient with metastatic breast cancer.
    Clinical breast cancer, 2015, Volume: 15, Issue:2

    Topics: Breast Neoplasms; Female; Humans; Hypertension, Pulmonary; Imatinib Mesylate; Middle Aged; Neoplastic Cells, Circulating; Protein Kinase Inhibitors; Thrombotic Microangiopathies

2015
Secondary thrombotic microangiopathy in two patients with Philadelphia-positive hematological malignancies treated with imatinib mesylate.
    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2016, Volume: 22, Issue:2

    Topics: Aged; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Protein Kinase Inhibitors; Thrombotic Microangiopathies

2016
Platelet-derived growth factor receptor-tyrosine kinase inhibitor, imatinib, is effective for treating pulmonary hypertension induced by pulmonary tumor thrombotic microangiopathy.
    International heart journal, 2015, Volume: 56, Issue:2

    Topics: Adenocarcinoma; Antineoplastic Agents; Benzamides; Female; Humans; Hypertension, Pulmonary; Imatinib Mesylate; Lung Neoplasms; Middle Aged; Piperazines; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Stomach Neoplasms; Thrombotic Microangiopathies

2015